SOHO 2023
The meeting had more than 2,500 registrants attending in person or online.
The award was created in honor of Michael J. Keating, MD, a founding member and past president of SOHO.
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
Advertisement
Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee.
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Advertisement
Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products.
Swaminathan Iyer, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss advances in T-cell lymphoma.
Alessandra Ferrajoli, MD, discusses her presentation on the topic during the Eleventh Annual Meeting of SOHO.
Dr. Anderson spoke about her plenary session on the topic at the Eleventh Annual Meeting of SOHO.
All patients included in the study required treatment and had not previously received psychiatric treatment.
The study included patients with relapsed or refractory B-cell malignancies who were in the phase I/II BRUIN trial.
The researchers investigated if iso-cel in patients with relapsed or refractory CLL is a cost-efficient option.
Noteworthy regional disparities were noticed in treatment strategies.
The phase II study evaluated liso-cel in patients with relapsed or refractory follicular lymphoma.
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Intratumoral hypoxia could be associated with CAR-T outcomes in patients with non-Hodgkin lymphoma.
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.